BioCentury | Jan 8, 2021
Emerging Company Profile

Impact founder Hood launches Endeavor with $62M to address pulmonary diseases

...to address pulmonary dysfunction. Hood said taladegib has demonstrated greater potency and safety than hedgehog inhibitor Erivedge vismodegib...
...lung function, which no other agent does, but it was too toxic,” said Hood. Roche markets Erivedge...
...John HoodPatents: Multiple issued composition of matter patents on taladegib Danielle Golovin taladegib (LY2940680) Erivedge, vismodegib (GDC-0449, RG3616, Systemic Hedgehog Pathway Inhibitor) Daurismo...
BioCentury | Jun 25, 2019
Distillery Therapeutics

Herb-derived flavonoid identified as potential TNBC treatment

...model of TNBC, the compound decreased tumor weight by 55%. Marketed SMO antagonists include Erivedge vismodegib...
...Odomzo sonidegib from Sun Pharmaceutical Industries Ltd. Both are approved for basal cell carcinoma (BCC). Erivedge...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

...Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge vismodegib...
...tumor burden compared with Erivedge alone. Also in the residual BCC model following treatment with Erivedge...
...CONTACT: Frederic de Sauvage, Genentech Inc., San Francisco, Calif. email: desauvage.fred@gene.com Claire Quang Erivedge, vismodegib (GDC-0449, RG3616, Systemic Hedgehog Pathway Inhibitor) Free...
BioCentury | Sep 19, 2017
Distillery Therapeutics

Cancer

...and PTCH1 , another hedgehog pathway component, with potencies comparable to the SMO antagonist Erivedge vismodegib...
...The Genentech Inc. unit of Roche , Chugai Pharmaceutical Co. Ltd. and Curis Inc. market Erivedge...
BioCentury | Mar 10, 2017
Financial News

Curis secures $45M loan tied to royalties

...from HCR, repayable with 9.95% interest exclusively using royalty payments derived from sales of Erivedge vismodegib...
...ranging from 5-7.5% on Erivedge sales. In its earnings, the company said 2016 sales of Erivedge...
...2016, Curis reported a loss of $60.4 million on revenues of $7.5 million, primarily from Erivedge...
BioCentury | Mar 10, 2017
Financial News

Curis completes debt financing

...9.95% and is repayable exclusively using royalty payments derived from sales of cancer drug Erivedge vismodegib...
BioCentury | Dec 9, 2016
Clinical News

Erivedge regulatory update

...Curis said EMA’s CHMP granted full approval to Erivedge vismodegib to treat adult patients with symptomatic...
...Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Erivedge vismodegib ( GDC-0449 , RG3616) Business: Cancer Julian Zhu Erivedge GDC-0449 RG3616 vismodegib Curis...
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | Jun 13, 2016
Company News

Curis, Genentech, Roche sales and marketing update

...Health Care (IQWiG) said in a second early benefit assessment that added benefit for Erivedge vismodegib...
...indication. In 2014, Germany’s Federal Joint Committee (G-BA) said in a final benefit assessment that Erivedge...
BioCentury | Jun 13, 2016
Product Development

Basket cases

...melanoma drug Zelboraf vemurafenib in tumors with BRAF mutations; basal cell carcinoma (BCC) drug Erivedge vismodegib...
...39%) with V600E mutations responded. Two of eight patients with hedgehog pathway mutations responded to Erivedge...
...baskets. " BioCentury (2015) Tables Basket designs MyPathway Product(s) MOA/target Molecular alteration Approved indication(s) Erivedge vismodegib...
Items per page:
1 - 10 of 134